These findings underscore the emerging role of SEMA3C in promoting ER+ breast cancer growth and survival and suggest that targeting SEMA3C may represent a potential therapeutic strategy for ER+ breast cancer patients. This evidence concerns the gene SEMA3C and breast carcinoma.